ADDIA a project to remember
ADDIA  a project to remember  

Consortium at a glance

ADDIA consortium is coordinated by Amoneta Diagnostics S.A.S., a French SME developing biomarker-based diagnostic

products for neurodegenerative diseases. For more information on Amoneta Diagnostics: www.amoneta-diagnostics.com

 

Firalis S.A. is the parent company of Amoneta Diagnostics and a participant of ADDIA project. Firalis is a leader SME in biomarker R&D, developing innovative diagnostic solutions, in particular for cardiovascular diseases and toxicities.
For more information on Firalis, please visit
 
www.firalis.com

 

The ADDIA Consortium, started in Aug-2015 and funded by the E.C. within the franework of Horizon-2020/PHC-12 program, will realize an observational multicenter Proof-of-Performance (PoP) clinical trial, in participation of following clinical research centers: 

 

  • The University Hospital of Strasbourg, Strasbourg/FR,
    Dr. Frédéric BLANC
  • The Colmar Hospital, Colmar/FR,
    Dr. François SELLAL
  • The Leenaards Memory CenterLausanne/CH, 
    Centre Hospitalier Universitaire Vaudois (CHUV)

    Prof. Jean-François DEMONET
  • National Alzheimer's Center, Brescia/IT,
    Dr. Moira MARIZZONI
  • Assistance Publique - Hôpitaux de Paris (AP-HP), Paris/FR
    Prof. Bruno DUBOIS
  • Istanbul Faculty of Medicine,
    Department of Neurology, İstanbul/TR,
    Prof. Dr. Hakan GÜRVİT
  • Hôpital Roger Salengro, Lille/FR
    Centre Hospitalier Régional Universitaire (CHRU)
    Pr. Florence PASQUIER

     
  • Cliniques Universitaires Saint Luc, Brussels/BE
    Université Catholique de Louvain (UCL)
    Pr. Adrian IVANOIU

     
  • Hôpitaux Universitaires de Genève, Geneva/CH
    Pr. Giovanni B. FRISONI

 

 

For more information, do not hesitate to contact us.

 

ADDIA Project Kick-off Meeting in Huningue, 02-10-15

ADDIA is funded by HORIZON 2020
Research & Innovation Programme
< E.C. Grant Agreement # 674474 >

Version imprimable Version imprimable | Plan du site
© Amoneta Diagnostics SAS